Tel Aviv - Delayed Quote ILA

Evogene Ltd. (EVGN.TA)

430.00

+18.50

+(4.51%)

As of 10:19:33 AM GMT+3. Market Open.

Evogene Schedules First Quarter 2025 Financial Results Release

May 8, 2025 - Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the first quarter of 2025, on Wednesday, May 21, 2025.

PR Newswire 5 days ago

EVGN
Why Evogene Ltd. (EVGN) Soared on Monday

We recently compiled a list of the 10 Micro-, Small-Cap Companies Lead Monday’s Charge. In this article, we are going to take a look at where Evogene Ltd. (NASDAQ:EVGN) stands against the other stocks. The stock market ended the first trading day of the week in the negative territory, with all major indices recording hefty losses, […]

Insider Monkey 21 days ago

EVGN.TA
+4.51%
ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire Evogene's MicroBoost AI for AG platform.

PR Newswire 22 days ago

EVGN
Evogene Ltd (EVGN) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Evogene Ltd (EVGN) reports significant revenue increase and strategic partnerships, despite ongoing challenges in R&D and operating expenses.

GuruFocus.com 2 months ago

EVGN.TA
+4.51%
Evogene: Q4 Earnings Snapshot

REHOVOT, Israel (AP) — Evogene Ltd. (EVGN) on Thursday reported profit of $427,000 in its fourth quarter. On a per-share basis, the Rehovot, Israel-based company said it had profit of 6 cents. The agricultural company posted revenue of $1.6 million in the period.

Associated Press Finance 2 months ago

EVGN.TA
+4.51%
Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the fourth quarter and full year period ended December 31, 2024.

PR Newswire 2 months ago

EVGN
Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced the appointment of Mr. Nir Nimrodi as the new Chairperson of the Board, succeeding Ms. Sarit Firon, who has held the position since August 2021. Ms. Firon will continue to serve as a member of the Board.

PR Newswire 2 months ago

EVGN
Evogene Schedules Fourth Quarter 2024 Financial Results Release

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025.

PR Newswire 2 months ago

EVGN
AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced the breakthrough discovery of a novel Mode of Action (MoA) active against Zymoseptoria tritici, the fungal pathogen responsible for Septoria tritici blotch (STB), one of the most devastating diseases affecting wheat crops globally. Through extensive virtual screening of large compound libraries and subsequent experimen

PR Newswire 2 months ago

EVGN
Evogene Ltd (EVGN) Q3 2024 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities

Despite a dip in quarterly revenue, Evogene Ltd (EVGN) advances with strategic collaborations and promising future prospects.

GuruFocus.com 5 months ago

EVGN.TA
+4.51%
Evogene: Q3 Earnings Snapshot

REHOVOT, Israel (AP) — Evogene Ltd. (EVGN) on Thursday reported a loss of $7.6 million in its third quarter. The Rehovot, Israel-based company said it had a loss of $1.31 per share. The agricultural company posted revenue of $1.8 million in the period.

Associated Press Finance 5 months ago

EVGN.TA
+4.51%
Evogene Reports Third Quarter 2024 Financial Results

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene" or the "Company"), a leading computational biology company aiming to revolutionize the development of life-science-based products, today announced its financial results for the third quarter period ended September 30, 2024.

PR Newswire 5 months ago

EVGN
Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced significant progress in the development of its LAV321 bio-fungicide, targeting downy mildew. Over three years of field trials across Europe, evaluating the efficacy of LAV321 in protecting crops from fungal diseases, LAV321 demonstrated an impressive average efficacy rate of 70% against downy mildew in grapes. These results lead to the decision to advance it to the last st

PR Newswire 5 months ago

EVGN
Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced the commercial expansion of Yalos® seed-treatment to soybean, following successful field trials performed in 2024 in the US. Yalos®, Lavie Bio's first commercial bio-inoculant product available in the US and Canada, demonstrated yield increase by more than 5% on average, in soybean.

PR Newswire 5 months ago

EVGN
Evogene Schedules Third Quarter 2024 Financial Results Release

Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the third quarter of 2024, on Thursday, November 21, 2024.

PR Newswire 6 months ago

EVGN
Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced a collaboration with Google Cloud to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene's ChemPass AI tech-engine to new levels of innovation. ChemPass AI is a computational technology platform that directs and accelerates the discovery and development of novel products

PR Newswire 6 months ago

EVGN
Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Casterra Ag Ltd. ("Casterra"), an integrated castor cultivation solution company for oil production for bio-based products and biofuel, and a subsidiary of Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), today announced a key milestone in its operational expansion plan in Africa with the delivery of its first shipment of over 100 tons of castor seeds to its customer in Africa, seeds that were cultivated at several sites in Kenya and processed in a seed production facility near Naivasha, Ke

PR Newswire 6 months ago

EVGN
Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd. ("Evogene") (NASDAQ: EVGN)(TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, together with Ben-Gurion University (BGU), a renowned Israeli academic research institution, announced receiving an approval from IIA for a second year grant to continue developing CRISPR technology for crust

PR Newswire 7 months ago

EVGN
Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced receiving a grant from the Israel Innovation Authority (IIA) to advance its program to develop a breakthrough technology for the delivery of ag-biologicals to agriculture. This patented technology, named 'MicroFermentor', is based on an innovative microbe formulation that enables the multiplication of beneficial bacteria directly on the plant, reducing application costs, exten

PR Newswire 7 months ago

EVGN
Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Evogene Ltd. ("Evogene" or the "Company") (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, announced today that it has entered into definitive agreements with a single health-care focused institutional investor for the purchase and sale of 1,692,308 ordinary shares (or ordinary share equivalents in lieu thereof)

PR Newswire 8 months ago

EVGN

Performance Overview

Return	EVGN.TA	TA-125 (^TA125.TA)
YTD	-40.84%	+10.66%
1-Year	-83.38%	+32.21%
3-Year	-85.73%	+38.31%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Evogene Ltd. (EVGN.TA)

Evogene Schedules First Quarter 2025 Financial Results Release

Why Evogene Ltd. (EVGN) Soared on Monday

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Evogene Ltd (EVGN) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Evogene: Q4 Earnings Snapshot

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Evogene Schedules Fourth Quarter 2024 Financial Results Release

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Evogene Ltd (EVGN) Q3 2024 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities

Evogene: Q3 Earnings Snapshot

Evogene Reports Third Quarter 2024 Financial Results

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Evogene Schedules Third Quarter 2024 Financial Results Release

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Casterra Announces a Key Milestone in its Operational Expansion Plan in Africa, with Completion of First Shipment of Castor Seeds Grown and Processed in Kenya

Watershed AC, Evogene and Ben-Gurion University Receive Approval for Second Year Grant to Continue the Collaboration Focused on Improving Crustacean Traits Utilizing Gene Editing Technology

Lavie Bio Receives Grant from Israel Innovation Authority to Advance the Development of 'MicroFermentor', a Unique Technology that Can Change the Economics of Ag-Biologicals

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement

Performance Overview